PUBLISHER: The Business Research Company | PRODUCT CODE: 1942509
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942509
Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.
The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.
Tariffs are influencing the cancer diagnostics market by increasing costs of imported sequencing platforms, imaging systems, reagents, consumables, and laboratory automation equipment. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to heavy reliance on imported diagnostic technologies, while Asia-Pacific faces higher procurement costs for advanced testing platforms. These tariffs are raising testing costs and slowing laboratory expansion plans. At the same time, they are encouraging regional manufacturing of diagnostic kits, localized reagent production, and increased focus on cost-efficient diagnostic innovation.
The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cancer diagnostics market size has grown rapidly in recent years. It will grow from $25.5 billion in 2025 to $28.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, increased investments in oncology research, expansion of hospital diagnostic infrastructure, growing adoption of imaging-based cancer detection, improvements in laboratory automation.
The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.
Rising healthcare expenditure is expected to drive growth in the cancer diagnostics market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. The growing demand for healthcare spending is largely driven by the increasing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure supports cancer diagnostics by enabling the adoption of advanced screening technologies and expanding access to early detection services. Investments in modern equipment and specialized laboratories enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is fueling the growth of the cancer diagnostics market.
The increasing incidence of lung cancer is another key factor driving the cancer diagnostics market. Lung cancer originates in the lung tissues, where abnormal cells grow uncontrollably, forming tumors that may spread to other parts of the body. Cancer diagnostic devices are essential for detecting, diagnosing, and monitoring lung cancer, helping healthcare professionals determine its presence, type, stage, and guide treatment decisions. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based organization, estimated that 238,340 people in the United States would be diagnosed with lung cancer in 2023, up from 236,000 cases in 2022. Therefore, the rising incidence of lung cancer is contributing to the expansion of the cancer diagnostics market.
Major companies operating in the cancer diagnostics market are focusing on artificial intelligence (AI)-driven innovations to improve diagnostic precision and efficiency. AI-based tools analyze tissue samples and clinical data to aid pathologists in identifying cancerous and non-cancerous regions. For example, in March 2023, Qritive, a Singapore-based developer of AI-powered diagnostic solutions, launched QAi Prostate. This advanced AI-powered tool assists in prostate cancer diagnosis by using machine learning algorithms to accurately detect and classify malignant and benign areas in prostate tissue samples, supporting pathologists in making informed diagnostic and treatment decisions.
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cancer diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.